Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology

Zaher Armaly, Mazen Elias, Rabah Yasin, Munir Hamzeh, Adel R. Jabbour, Suheil Artoul, Amer Saffouri

Patient: Female, 89
Final Diagnosis: Tumor lysis syndrome (TLS)
Symptoms: Dyspnea
Medication: Steroids
Clinical Procedure: HD
Specialty: Nephrology

Background: Tumor lysis syndrome is common in hematological malignancy, but less frequent in chronic and solid tumors. Almost always it is observed after chemotherapy or radiotherapy initiation, but rarely occurs spontaneously.

Case Report: A 89-year-old female with stable chronic lymphocytic leukemia was admitted to the hospital because of worsening dyspnea and dry cough. Her vital signs were normal, except for sinus tachycardia. On physical examination, she appeared distressed, dyspneic, sweaty but afebrile, anxious, but alert and well oriented. Lung examination revealed reduced air entry with bibasilar crackles. No peripheral edema was seen, pulses were normal, and no signs of deep vein thrombosis were observed. Laboratory analysis revealed leukocytosis; but normal hematological and biochemical parameters. Intravenous (IV) furosemide and antibiotics (IV ceftriaxone and orally azithromycin) were started along with steroid therapy (methylprednisolone 62.5 mg, IV). The treatment with steroids lasted for 1 day only, and in the following day, the patient was switched to prednisone (20 mg/day orally) for only 1 additional day. White blood cell count increased on day 1, 2 and 3 after admission, along with development of hyperuricemia, hyperphosphatemia, hyperkalemia, acute renal failure and elevated troponin levels. Hemodiafiltration/hemodialysis was initiated, and the patient was discharged after serum concentrations of these electrolytes and kidney function were restored. One month after discharge, the patient denied any malaise and was at stable condition.

Conclusions: Herein, we present a case of a patient with stable chronic lymphocytic leukemia, who developed spontaneous tumor lysis syndrome after short low dose of steroid therapy. This case highlights the importance of including spontaneous tumor lysis syndrome in the differential diagnosis of any acute renal failure in the constellation of any malignancy.

MeSH Keywords: Acute Kidney Injury • Hemodialysis Units, Hospital • Leukemia, Lymphocytic, Chronic, B-Cell • Tumor Lysis Syndrome

Conflict of interest: None declared

Corresponding Author: Zaher Armaly, e-mail: zaherarmaly@nazhosp.com
Background

Tumor lysis syndrome (TLS) is a life threatening oncologic and nephrologic complication of acute hematological malignancy [1–5], but less frequent in chronic and solid tumors [6–9]. Usually it is observed after chemotherapy or radiotherapy initiation, but rarely occurs spontaneously (STLS) [10–16]. TLS is characterized by the release into the systemic circulation of several intracellular components following lysis of tumor cells, with consequent hyperkalemia, hyperphosphatemia, hyperuricemia, hypermagnesemia and hypocalcemia [3,17,18]. If left untreated these aberrancies in electrolyte balance may lead to death from fatal arrhythmias, seizures and severe acute renal failure [1,2,4,5,19].

Case Report

We report a case of an 89-year-old female known to suffer from stable chronic lymphocytic leukemia (CLL) for more than 40 years, without any related treatment for the last 15 years. She was otherwise in relatively good health with no history of hypertension, coronary disease, recurrent infections or hospitalization.

Her usual white blood cell (WBC) counts were approximately 12–15×10^9/L and her hemoglobin levels were 12 g%. Kidney function was normal as was evident by serum creatinine (Scr) of 0.76 mg/dL (eGFR=66.4 mL/min, according to CKD-EPI) (Table 1). Her body mass index (BMI) was 18 kg/m^2.

She was admitted to the hospital because of worsening dyspnea and dry cough. Prior to her admission, she was treated with antibiotic (azithromycin 250 mg twice daily) for 1 week due to upper respiratory tract infection (URI).

She denied fever, chest pain, gastrointestinal or urinary symptoms. Her vital signs were normal, except for sinus tachycardia 112 beats/min. On physical examination, she appeared distressed, anxious, but alert and well oriented. She was dyspneic (RR 36 breaths/min), sweaty but afebrile. There was no rash, pharyngitis, or signs of sinusitis.

Heart sounds were normal. Lung examination revealed reduced air entry with bibasilar crackles. Palpable axillary lymphadenopathies were found. Abdomen was soft without organomegaly. No peripheral edema was seen, pulses were normal, and no signs of deep vein thrombosis were observed.

**Laboratory tests on admission**

WBC 67×10^9/L, neutrophils 5%, lymphocytes 78%, hemoglobin (Hb) 11.2 g%, hematocrit (Hct) 33, platelets 72×10^9/L, serum creatinine 0.76 mg/dL, potassium 4.9 mEq/L, blood sugar 122 mg/dL, blood urea nitrogen (BUN) 24 mg/dL, calcium 8.9 mg/dL, phosphorus 4 mg/dL, albumin 4.6 g/dL (normal range 3.5–5.2), total protein 6.5 g/dL (normal range, 6.6–8.3), C-reactive protein (CRP) 0.9 mg/L (normal range 0–0.5), and liver enzymes and lipid profile were normal (Table 1). Uric acid and lactate dehydrogenase (LDH) were not available.

Venous blood gases: pH 7.32, partial pressure of carbon dioxide (pCO2) 51 mmHg, bicarbonate (HCO3) 26 mmol/L.

Chest x-ray (CXR) revealed enlarged cardiac silhouette, pulmonary congestion, and an infiltration in the left lower lobe, which consisted with pneumonia or as part of the congestion (Figure 1).

Intravenous (IV) furosemide and antibiotics (IV ceftriaxone and oral azithromycin) were started along with IV steroids therapy (methylprednisolone 62.5 mg) for upper respiratory infection (URI). The treatment with antibiotics lasted for 1 week and steroids lasted for 1 day only, and in the following day, the patient was switched to prednisone (20 mg/day orally) for only 1 additional day.

On day 1 of her admission, CXR was improved and no more infiltration was seen. *Staphylococcus Epidermidis* was

| Lab Variable | On admission | Day 1 | Day 2 | Day 3 | At Discharge | After 30 days | Reference range |
|--------------|--------------|------|------|------|--------------|---------------|----------------|
| WBC (x10^9/L) | 67           | 157  | 135  | 190  | 94           | 12            | 4.5–11.5        |
| Uric acid (mg/dL) | –             | –    | 20.4 | 42.5 | 9.7          | 5.6           | 2.6–6.0         |
| Potassium (mg/dL) | 4.9          | 5.1  | 4.6  | 6.94 | 3.8          | 4.6           | 3.5–5.1         |
| Phosphorus (mg/dL) | 4.9          | –    | 7.8  | 26.3 | 2.6          | 3.8           | 2.5–5.0         |
| Creatinine (mg/dL) | 0.76         | 0.69 | 1.63 | 2.2  | 0.78         | 0.44          | 0.51–0.95       |
| BUN (mg/dL)    | 24           | 27   | 55   | 107  | 39           | 21            | 8.5–21.5        |
| LDH (U/L)      | –            | –    | 966  | 1135 | 694          | 645           | 230–480         |
grown in the first blood culture, but no further growth was seen in the following blood cultures, and so the first culture was considered to be a contamination. Urine antigen (Ag) for Legionella and Streptococcus Pneumoniae were also negative.

WBC 157×10^3/uL, lymphocytes 69%, neutrophils 4%, Hb 12.1 g%, Hct 36, platelets 129×10^3/uL, serum creatinine 0.69 mg/dL, BUN 107 mg/dL, sodium 133 mEq/L, potassium 6.94 mEq/L, LDH 1135 U/L, phosphorus 3.55 mg/dL, pH 7.30, HCO3 16 mmol/L, PCO2 45 mmHg, AG 21, WBC 190×10^3/uL, lymphocytes 64%, neutrophils 5%, Hb 9.6 g/dL, and platelets 166×10^3/uL (Table 1).

The latter is a clinical condition in which CLL changes into a fast-growing type of lymphoma. Conservative treatment as a first step therapy was instituted by giving intravenous fluids along with bicarbonate in the presence of metabolic acidosis. In addition, febuxostat (80 mg/day) as well as sevelamer (2.4 g/day) were initiated.

On day 2, the patient developed oliguric acute renal failure (100 mL/24 hours), with serum creatinine 1.63 mg/dL, BUN 55 mg/dL, perfusion index (PI) 7.8 mg/dL, magnesium (Mg) 2.9 mg/dL, uric acid 20.4 mg/dL, calcium 8.3 mg/dL, WBC 135×10^3/uL, platelets 129×10^3/uL, Hb 12.1 g/dL, LDH 966 U/L, pH 7.30, and HCO3 17 mEq/L (Table 1). A diagnosis of tumor lysis syndrome (TLS) was raised as a differential diagnosis, despite not having any prior knowledge whether CLL can be complicated by TLS without any chemotherapy, radiotherapy, high dose steroids therapy or evolution to Richter’s syndrome.

On day 3, the patient became anuric with further deterioration of blood tests: PI 26 mg/dL, uric acid 42 mg/dL, calcium 7.2 mg/dL, magnesium 3.55 mg/dL, LDH 966 U/L, BUN 107 mg/dL, serum creatinine 2.2 mg/dL, sodium 133 mEq/L, potassium 6.94 mEq/L, LDH 1135 U/L, pH 7.30, HCO3 16 mmol/L, PCO2 45 mmHg, AG 21, WBC 190×10^3/uL, lymphocytes 64%, neutrophils 5%, Hb 9.6 g/dL, and platelets 166×10^3/uL (Table 1).

A diagnosis of TLS was confirmed, and urgent long hemodialysis was initiated. A total of only 3 consecutive sessions of initially hemodialysis followed by hemodiafiltration were sufficient to achieve a full recovery of kidney functions and electrolytes balance. Her serum creatinine was 0.78 mg/dL, BUN 39 mg/dL, calcium 7.5 mg/dL, PI 2.6, LDH 694 U/L, uric acid 9.7 pH 7.43, HCO3 25.5, and pCO2 39 (Table 1).

The patient was discharged home with a hemodynamically stable condition.

1 month later, her WBC was 12×10^3/uL, lymph 69%, platelets 103×10^3/uL, serum creatinine 0.44 mg/dL, BUN 21 mg/dL, potassium 4.6 mEq/L, calcium 8.2 mg/dL, uric acid 5.6 mg/dL, and LDH 645 U/L (Table 1).

**Discussion**

TLS is a well-recognized both nephrologic and oncologic emergency and an urgent treatment is needed accordingly. If an immediate treatment is not instituted this complication can end with death [2,15,20].

TLS is usually seen in highly proliferative malignant lymphomas, leukemia (such as Burkitt’s lymphoma and acute lymphoid leukemia) [1,2] after cytotoxic chemotherapy and radiotherapy initiation [3]. Less frequently, TLS is seen after high dose steroid therapy [4,16], or even before initiation appropriate therapy [19].

In chronic hematologic malignancies, TLS is rarely observed [5,6,10] as well as in solid malignancies [7,8]. This is due to both slow rate of proliferation and response to chemotherapy. However, in highly proliferative and bulky chemosensitive tumors, spontaneous TLS (STLS) can be seen [11–14,17,18,21,22].

Nowadays, even these chronic malignancies showed an increased frequency of TLS owing to new target therapies [15,20].
TLS is characterized by the release into the systemic circulation of several intracellular components such as potassium, phosphorous, nucleic acids, and magnesium from lysis of tumor cells, with consequent hyperkalemia, hyperphosphatemia, hyperuricemia, hypermagnesemia, and hypocalcemia, as in our case [2,23]. If left untreated, these aberrancies in electrolyte balance may lead to death due to fatal arrhythmias, neurologic complications (seizures) and chronic dialysis due to end stage renal disease (ESRD) [3,15,20,23].

Our patient meets both the Cairo-Bishop criteria [11] as well as the Howard criteria [2] for TLS. The Cairo-Bishop criteria requires 2 or more defined laboratory abnormalities with a 25% change from baseline occurring at any time within 3 days prior or 7 days after chemotherapy [20], and the Howard criteria which is a modification of the Cairo-Bishop criteria, omits the need for a 25% change in laboratory values and instead adds that the 2 or more defined laboratory abnormalities (based on absolute values) must present within a 24-hour period to meet the definition of laboratory TLS [2].

Herein we present a rare case in the literature that describes a STLS in a stable CLL patient, which later quickly resolved after only 3 sessions of hemodialysis without any sequelae. Similar findings were reported by Tufan et al. [19], who described spontaneous TLS in a patient with diffuse large B cell lymphoma and Richter syndrome (RS). The latter is a clinical condition in which CLL changes into a fast-growing type of lymphoma that could be the same process described in the present case. Specifically, diffuse large B cell lymphoma may develop into RS following CLL. Development of RS was reported in about 2.2% to 8% of cases during the clinical course of CLL [24].

However, we could not exclude that the administration of steroids even in very small dose for 2 days triggered TLS in our patient. In this context, Coutinho et al. [16] reported TLS in a case of CLL 48 hours following treatment with high-dose corticosteroids (2 doses of 2 gr methylprednisolone). Likewise, Vaisban et al. [4] reported a case of TLS in patient with CLL that was treated by high dose corticosteroids. Although TLS was described in high-grade lymphoproliferative disorders after the use of corticosteroids, our case along those of Coutinho [16] and Vaisban [4] are the only reports in the literature of TLS induced by corticosteroids used as a single agent in CLL. However, the present case is the first one to show that administration of even low steroid doses for short period to CLL patients may cause TLS. Unfortunately, the mechanisms underlying steroids induced LTS in CLL is unknown, and additional studies in this regard are needed. However, the cytotoxic action of the glucocorticoids is thought to be mediated by specific cytoplasmic receptors, via which the steroids form a complex [25]. Glucocorticoids have been shown to damage lymphoid cells by a number of pathways: including inhibition of DNA synthesis changing the membrane structure and cytolysis [25].

The rarity of this complication should prompt us to consider it in future cases of CLL. Furthermore, this case emphasizes the importance of continued awareness and prompt treatment.

**Conclusions**

Herein, we present a rare case of a patient with stable CLL, who developed either STLS or steroid-induced TLS. As STLS has never been reported in a patient with CLL, we could not exclude that this phenomenon developed due to steroid administration even at low doses. This case highlights the importance of including STLS/SLT in the differential diagnosis of any acute renal injury in the constellation of any malignancy.

**Acknowledgements**

The authors thank Safa Kinaneh, Department of Nephrology, Nazareth Hospital for her technical support.

**Conflicts of interest**

None.

**References**

1. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med, 1993; 94(2): 133–39

2. Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med, 2011; 364(19): 1844–54

3. Cairo MS, Coiffier B, Reiter A, Younes A: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol, 2010; 149(4): 578–86

4. Vaisban E, Zaina A, Braester A et al: Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia. Ann Hematol, 2001; 80(5): 314–15

5. Jensen M, Winkler U, Manzke O et al: Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol, 1998; 77(1–2): 89–91

6. Cech P, Block JB, Cone LA, Stone R: Tumor lysis syndrome after tamoxifen flare. N Engl J Med, 1986; 315(4): 263–64

7. Mirakhimov AE, Ali AM, Khan M, Barbaryan A: Tumor lysis syndrome in solid tumors: An up to date review of the literature. Rare Tumors, 2014; 6(2): 5389

8. Gemici C: Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol), 2006; 18(10): 773–80

9. Fa’ak F, Vanegas D, Osei KM: A case report of atezolizumab induced tumor lysis syndrome. Am J Case Rep, 2019; 20: 785–89
10. Al-Kali A, Farooq S, Tfayli A: Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther, 2009; 34(5): 607–10

11. Shenoy C: Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung. QJM, 2009; 102(1): 71–73

12. Feld J, Mehta H, Burkes RL: Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: A case report. Am J Clin Oncol, 2000; 23(5): 491–93

13. Elfar A, Teleb M, Rodriguez C, Nahleh Z: Spontaneous tumor lysis syndrome in breast cancer: A case report and discussion. J Cancer Ther Res, 2013; 2(1)

14. Sklarin NT, Markham M: Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol, 1995; 18(1): 71–73

15. Cairo MS, Bishop M: Tumour lysis syndrome: New therapeutic strategies and classification. Brit J Haematol, 2004; 127(1): 3–11

16. Coutinho AK, de OSM, Pinczowski H et al: Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids. Am J Hematol, 1997; 54(1): 85–86

17. D’Alessandro V, Greco A, Clemente C et al: Severe spontaneous acute tumor lysis syndrome and hypoglycemia in patient with germ cell tumor. Tumori, 2010; 96(6): 1040–43

18. Pentheroudakis G, O’Neill VI, Vasey P, Kaye SB: Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer, 2001; 9(7): 554–57

19. Tufan A, Unal N, Koca E et al: Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome. Ann Hematol, 2006; 85(3): 183–84

20. Howard SC, Trifillo S, Gregory TK et al: Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: A systematic review. Ann Hematol, 2016; 95(4): 563–73

21. Lin CJ, Hsieh RK, Lim KH et al: Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. South Med J, 2007; 100(9): 916–17

22. Na YS, Park SG: A rare case of spontaneous tumor lysis syndrome in idiopathic primary myelofibrosis. Am J Case Rep, 2019; 20: 146–50

23. Sarno J: Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol, 2013; 4(2): 101–6

24. Tsimberidou AM, Keating MJ: Richter syndrome: Biology, incidence, and therapeutic strategies. Cancer, 2005; 103(2): 216–28

25. Galili U, Prokocimer M, Izak G: The in vitro sensitivity of leukemic and normal leukocytes to hydrocortisone induced cytolysis. Blood, 1980; 56(6): 1077–81